After peaking at over $18 per share in 2015, Opko Health's (NASDAQ: OPK) shares have since sold off thanks to lackluster sales of its first commercial-stage products, declining performance at its laboratory services business, and a high-profile, clinical-stage trial failure. Recently, shares have been rallying on hopes that Opko Health can turn it around.
Is Opko Health Getting Its Mojo Back?
newsfeedback@fool.com (Todd Campbell), The Motley Fool
Tue, 07/31/2018 - 6:31pm
BING NEWS:
- OPKO Health Announces Progress in EBV Vaccine Study, Stock Gains
OPKO Health, Inc.’s OPK company, ModeX Therapeutics Inc., announced the dosing of the first participant in the Phase I study (NCT06655324) of an Epstein-Barr virus (EBV) vaccine candidate yesterday.
01/8/2025 - 1:11 am | View Link - How drinking alcohol can affect your health
Moderate drinking was once thought to have benefits for the heart but better research methods have thrown cold water on that idea.
01/3/2025 - 4:58 am | View Link - More
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more